- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05943509
Hearing Program in Primary Care
Feasibility of a Hearing Program in Primary Care for Underserved Older Adults
During a primary care visit, investigators will screen and identify participants with hearing loss and then randomize to a) counseling on accessible assistive listening devices or b) referral to traditional audiology care pathway alone.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYC H+H/Bellevue
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- speaks English or Spanish;
- capacity to consent to research
Exclusion Criteria:
• has or uses hearing aids or cochlear implants
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Alternative Rehabilitation Strategies
Patients who screened positive for hearing loss and were randomized into the counselling on alternative rehabilitation strategies intervention arm. |
Counseling intervention. |
|
Active Comparator: Usual Care
Patients who screened positive for hearing loss and were randomized into the usual care audiology pathway control arm alone. |
Usual care audiology pathway. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Potential Participants Approached
Time Frame: Up to Month 3
|
Up to Month 3
|
|
Number of Potential Participants Screened
Time Frame: Up to Month 3
|
Up to Month 3
|
|
Percentage of Screened Participants with Hearing Loss
Time Frame: Up to Month 3
|
Up to Month 3
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Intervention Arm Participants who Complete Counseling Session
Time Frame: Up to Month 3
|
Up to Month 3
|
|
Percentage of Participants who Respond to Outreach to Confirm Recommendations within 72 Hours
Time Frame: Up to Month 3
|
Up to Month 3
|
|
Percentage of Participants who Respond to 3-Month Follow-Up
Time Frame: Month 3
|
Month 3
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Friedmann, NYU Langone Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-00648
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: David.friedmann@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD Sharing Time Frame
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD Sharing Access Criteria
The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to David.friedmann@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.